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Objective – The aim of the study was to determine the efficacy and 
safety of intravenous iron preparations in a group of children with 
iron deficiency anemia who did not respond to oral iron supplementa-
tion. Materials and methods – We conducted a retrospective study 
on children who received intravenous iron sucrose and iron gluconate 
at University Children’s Hospital Rijeka between January 1, 2010 and 
December 31, 2011. The response to therapy was determined by the 
difference in the hemoglobin values prior to parenteral treatment and 
after two months. Results – A total of 76 intravenous iron infusions 
were administered to twelve children. Patients had a good response 
to parenteral iron therapy, with a median hemoglobin rise of 2.7 g/dl 
within two months. There was only one mild adverse reaction. Con-
clusion – Parenteral iron therapy should be considered in a group of 
children with iron deficiency anemia who fail to respond to oral iron 
preparations due to malabsorption, intolerance or poor compliance. 
The possible occurrence of severe adverse reactions emphasizes the 
need for close medical observation.
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Introduction
Iron deficiency anemia (IDA) continues to 
represent a major public health problem, 
particularly in infants and young children. 
It is estimated that 40% to 50% of children 
under 5 years of age in developing countries 
are iron deficient (1). A common etiology of 
IDA is poor dietary iron intake, especially 
excessive consumption of cow’s milk. Other 
causes of IDA in children are increased iron 
requirements during the growth period, in-
adequate absorption or utilization of iron, 
and blood loss (2). The treatment consists of 
iron supplementation along with improved 
nutrition. In vast majority of iron-deficient 
anemic children, oral administration of sim-
ple ferrous salts provides effective and inex-
pensive therapy (3). Parenteral iron prepara-
tions are infrequently indicated, mainly for 
children with malabsorption or poor com-
pliance. Besides, some adverse reactions re-
ported with intravenous iron administration 
have led to its limited use in children (4). We 
conducted a retrospective study in which in-
travenous infusions of iron sucrose and iron 
gluconate where administered to pediatric 
patients with IDA who failed to respond to 
oral iron supplementation. 
The goal of the study was to determine 
the efficacy and safety of intravenous iron 
preparations. 
Original article
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Patients and methods
Medical records were reviewed on all patients 
who received intravenous iron preparations 
at the Division of Hematology and Oncol-
ogy, University Children’s Hospital Rijeka, 
between January 1, 2010 and December 31, 
2011. Data abstracted included age, gender, 
medical history leading to iron deficiency, un-
derlying disease, prior oral iron supplementa-
tion, indication for parenteral iron, laborato-
ry values before and after parenteral therapy, 
and adverse reactions. Stool was examined 
for the presence of blood and parasites. All 
tests were done at the same laboratory. The 
Institution Review Board approved this ret-
rospective study. The response to intravenous 
iron was determined by the difference in the 
hemoglobin concentration values prior to 
parenteral treatment and two months after 
the start of the treatment. Student t-test was 
performed with significance set at 0.05.  
Results
Twelve patients received intravenous iron 
during the study period. Children ranged in 
age from 13 months to 14 years (median 5.8 
years). Male to female ratio was 1 to 1. Be-
fore intravenous iron therapy, seven children 
underwent iron absorption test (10 mg/kg 
elemental iron, measuring serum iron imme-
diately before and 2 hours later) (6), which 
showed no increase in serum iron. In anemic 
children who were non-adherent to oral iron 
therapy, iron absorption test was not per-
formed. Patients, basic conditions leading 
to iron deficiency, indications for parenteral 
iron, total dosage and number of intravenous 
infusions are summarized in Table 1. 
Seven children, aged 1 to 3 years, had 
poor iron dietary intake. Two of them were 
twin boys who were born premature (birth 
weight 1700 g and 1800 g), fed with iron-
fortified formula, not started mixed food, 
and received no supplemental medical iron 
until the age of 11 months. Three adolescent 
girls had menorrhagia. One teenage girl had 
anemia due to insufficient iron intake and 
chronic gastritis. She was frequently tak-
ing antacids that contain calcium, thus de-
creasing absorption of iron from foods. One 
boy had documented cow’s milk allergy and 
chronic blood loss detected with chemical 
testing of stool specimens.
All patients were treated with oral iron 
(length of treatment varied by patient’s weight 
and compliance) before using parenteral deliv-
ery. Six patients had poor response to oral iron 
supplementation. Five children had low com-
Patient Sex Age(years) Etiology of iron deficiency Indication for parenteral iron
Total dose  
of iron (mg)
Number 
of doses
1 F 13 Menorrhagia Non-adherence to oral iron 1800 9
2 F 14 Menorrhagia Intolerance to oral iron 1400 7
3 F 14 Menorrhagia Intolerance to oral iron 1400 7
4 F 14 Chronic gastritis, Poor dietary intake No response to oral iron 2000 10
5 M 2 Cow’s milk allergy / Chronic blood loss Non-adherence to oral iron 125 2
6 M 2 Poor dietary intake No response to oral iron 375 6
7 M 2 Poor dietary intake Non-adherence to oral iron 375 6
8 F 3 Poor dietary intake Non-adherence to oral iron 375 6
9 M 1 Poor dietary intake, Premature twin No response to oral iron 375 6
10 M 1 Poor dietary intake, Premature twin No response to oral iron 375 6
11 F 2 Poor dietary intake No response to oral iron 250 4
12 M 2 Poor dietary intake Non-adherence to oral iron 437.5 7
Table 1 Characteristics of 12 patients receiving intravenous iron
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pliance; in three of these cases, there was low 
compliance by parents. Two adolescent girls 
claimed side effects as the main obstacles for in-
adequate iron supplementation. Only one pa-
tient had low toleration of the oral formulation. 
Iron was administered intravenously as 
iron sucrose (Venofer) and iron gluconate 
(Ferrlecit). Venofer is supplied in ampules of 
5 ml containing 100 mg of elemental iron. 
Each vial of 5 ml of Ferrlecit contains 62.5 
mg of elemental iron. The total amount of 
required iron was calculated according to the 
body weight and amount of desired change in 
hemoglobin using the following formula (5): 
Total dose of iron (mg) = [Target hemoglobin 
– actual hemoglobin] (g/dl) x weight (kg) x 
0,24 + [15 x weight (kg)]. Total cumulative 
dose was divided and given every 3 to 7 days 
(average time 6.3 days), until desired dose is 
achieved. Daily dosage was 5 to 7 mg of el-
emental iron per kilogram. Maximum single 
dose was 200 mg. Before administering the 
first dose to each patient, a test dose was ad-
ministered. For children weighting <10 kg, 
the test dose was 10 mg; for children weight-
ing 10 to 20 kg, the test dose was 15 mg; for 
other pediatric patients,  the test dose was 20 
mg. The test dose was diluted in 50 ml of 
0.9% sodium chloride and administered over 
60 minutes. If no adverse reactions were seen 
during infusion and after 30 minutes, the re-
maining dose was administered. Subsequent 
routine doses were given without a test dose. 
The iron preparation was diluted up to 0.8 
mg of elemental iron in 1 ml of normal saline 
solution and infused over 1 to 2 hours, de-
pending on dose and patient weight. Maxi-
mum dilution was 250 ml of normal saline.
Four patients received iron glucose and 
eight patients received iron gluconate. A total 
number of 76 doses was administered. The 
number of intravenous iron infusions per pa-
tient ranged from 2 to 10 (median 6.3), and 
the individual doses were 62.5 and 200 mg 
(median 108.3 mg). Twelve of the total 76 
doses were preceded by a test dose. 
Mean hemoglobin level before treatment 
was 8.7 g/dl (SD=1.7), ranging from 6.5 to 
10.6 g/dl. After two months mean hemoglo-
bin value was 11.7 g/dl (SD=1.0), ranging 
from 11.0 to 13.2 g/dl. Intravenous iron led 
to a significant increase (p<0.005) in hemo-
globin concentration of 2.7 g/dl within 2 
months (range 0.4 to 5.4 g/dl). Fig. 1 shows 
the response to intravenous iron prepara-
tions. 
Fig. 1 Hemoglobin levels before and 2 months after the beginning of intravenous iron therapy.
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anemia. In vast majority of cases, oral iron 
supplementation is effective, fast and inex-
pensive therapy. Infrequently, the response to 
oral iron preparations is unsatisfactory, most-
ly when malabsorption is present or when 
compliance is poor. In such cases parenteral 
iron is needed (10, 11).
Parenteral iron has been administered 
intramuscularly or intravenously. As intra-
muscular injections are painful, and have 
been linked with gluteal sarcoma, it is rec-
ommended that the use of intramuscular 
iron should be abandoned (12, 13). Several 
formulations of intravenous iron have been 
approved worldwide, including iron, sucrose, 
dextran, sucrose, gluconate, carboxymaltose, 
isomaltoside, and ferumoxytol (14, 15). The 
largest experience in published literature is 
with iron sucrose and iron gluconate, which 
we used in this study. Intravenous iron can be 
given in a variety of schedules. The frequency 
of therapy can be thrice weekly, twice weekly, 
weekly, or every other week, depending on 
the indication, pretreatment hematological 
values, target hemoglobin, response to ther-
apy, treating physician opinion, and center 
experience. The total amount of parenteral 
iron required to raise hemoglobin to normal 
levels and replenish iron stores is calculated 
according various formulas, and dosing cal-
culators are widely accessible. Dosing to chil-
dren should be adjusted to weight (1, 15).
There are very few studies on parenteral 
iron administration in pediatric practice for 
non-renal indication. Pinsk and coworkers 
reported an excellent response to intravenous 
iron sucrose in 45 children who failed previ-
ous treatment with oral iron (16). The best 
described series includes 38 children who re-
ceived iron sucrose; 13 with no response to 
previous oral iron, 13 with iron malabsorp-
tion or dependence on parenteral nutrition, 
7 with gastrointestinal blood loss, and 5 with 
other indications (17). Patients in all catego-
ries had a good response to intravenous iron.
Among 12 children who received a total 
of 76 doses of iron sucrose and gluconate, 1 
mild adverse reaction was attributed to the 
infusion. The patient experienced headache 
and transient mild hypotension one hour 
after the initiation of third intravenous iron 
sucrose, and the infusion was discontinued. 
Following intravenous iron administrations 
were uneventful. One patient had drug ex-
travasation, with pain and discoloration at 
the site of injection, which resolved within 
2 days. No other adverse reactions were re-
ported by patients or their parents. 
Discussion
IDA is the most common cause of anemia 
worldwide, particularly in children and wom-
en of childbearing age. In infants and young 
children, consumption of foods with low bio-
available iron is likely the primary contribut-
ing factor. Rapid growth may outpace dietary 
intake of iron, and result in iron deficiency 
without disease or apparently abnormal diet 
(7). Preterm and low-birth-weight infants are 
at greater risk for IDA. Other risks include 
inadequate iron absorption, chronic blood 
loss, and some other medical conditions that 
affect iron status (1). 
In the present study the main condition 
leading to IDA was poor dietary intake, 
mostly in young children. This finding points 
the importance of various dietary interven-
tions in the prevention of IDA, including 
breastfeeding, fortification of formula if not 
breast-fed, and in time introduction of iron-
containing complementary foods (8, 9). Ad-
olescent girls are at risk for IDA because of 
several factors, including menstrual bleeding, 
growth spurts, and fad dieting that restricts 
eating. Majority adolescents in this study had 
IDA due to heavy menstrual blood loss. Mea-
sures to alleviate menstrual disorders should 
be a part of the strategy to reduce IDA.
The goal of the therapy is both replenish-
ment of body iron stores and correction of 
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In our study, the most common reason to 
parenteral iron treatment was lack of the re-
sponse to oral iron. In this patient group, we 
performed oral iron absorption test, which 
confirmed disturbed intestinal iron absorp-
tion. Although failure to absorb iron is most-
ly due to an underlying malabsorption syn-
drome, prolonged IDA itself may impair in-
testinal absorption of iron in some children, 
thus necessitating parenteral iron for cor-
rection (6). Other indications for parenteral 
therapy in the present study included non-
adherence to oral therapy and intolerance to 
oral iron. Intolerance was not observed in 
young children, but in two adolescents who 
had gastrointestinal complaints. 
Eleven patients out of twelve showed im-
provement in hemoglobin levels at the end 
of the treatment. The only patient who had 
no significant increase in hemoglobin con-
centration was a 2-year-old boy with allergy 
to cow’s milk protein (no 5). The child had 
started with milk free diet including soy-
based formula that he tolerated well. His par-
ents were not adherent to a prescribed course 
of oral iron, and refused parenteral iron after 
two doses. 
Severe systemic reactions after parenteral 
iron administration have been reported in 
the literature, with possible fatal outcome. 
Iron dextran has higher incidence of anaphy-
laxis compared to iron sucrose and iron glu-
conate (18). Use of these preparations may 
rarely be associated with hypotension, flush-
ing, abdominal pain, and nausea/vomiting. 
Prior to initiating intravenous iron therapy, 
a one-time test dose has traditionally been 
given, but a limited value was noted. A test 
dose neither minimizes reactions to the first 
dose, nor prospectively identifies the patient 
at increased risk for a severe reaction to a 
later doses. Therefore, caution is warranted 
with every dose of intravenous iron formula-
tion that is administered (19).  Our group 
of patients tolerated parenteral iron very well, 
except one patient (no 3) who experienced 
a mild systemic reaction during the adminis-
tration of the third dose. Although the num-
ber of patients included in this study is small, 
our preliminary results suggest that paren-
teral iron therapy could be a safe and effica-
cious means to treat IDA in children who do 
not tolerate oral iron therapy for any reason. 
Reporting of adverse events to central agency 
should be mandatory.
Conclusion
Intravenous iron supplementation should be 
considered to treat IDA in children where 
oral administration has failed. The possible 
occurrence of systemic reactions emphasizes 
the need for very close medical supervision. 
Prospective studies involving larger popula-
tion are needed to clarify the proper indica-
tions of intravenous iron, and to determine 
the safety and efficacy of parenteral iron ther-
apy in children. 
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